



(51) International Patent Classification:

C07D 241/44 (2006.01) *A61P 3/04* (2006.01)
C07D 471/04 (2006.01) *A61P 3/10* (2006.01)
A61K 31/495 (2006.01)

(21) International Application Number:

PCT/EP2009/003538

(22) International Filing Date:

19 May 2009 (19.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08290564.7 16 June 2008 (16.06.2008) EP

(71) Applicant (for all designated States except US): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CRAVO, Daniel** [FR/FR]; 123, Avenue Jules Ferry, F-78500 Sartrouville (FR). **HALLAKOU-BOZEC, Sophie** [FR/FR]; 166 avenue Henri Ginoux, F-92120 Montrouge (FR). **LEP-IFRE, Franck** [FR/FR]; 12 Rue Rameau, F-91160 Longjumeau (FR).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: QUINOXALINEDIONE DERIVATIVES



(57) Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R¹, R², R³ are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.